Home LiteratureArticle Details
PMID: 8318413 Published · ppublish English Journal Article

Prognosis after resection of residual masses following chemotherapy for metastatic nonseminomatous testicular cancer: a multivariate analysis.

British journal of cancer ·Vol. 68 ·No. 1 ·1993-07-00 ·Pages 195-200

Steyerberg EW, Keizer HJ, Zwartendijk J, Van Rijk GL, Van Groeningen CJ, Habbema JD, Stoter G

Abstract

Following chemotherapy for metastatic nonseminomatous testicular cancer, 86 patients with normal serum markers AFP and HCG underwent resection of residual tumour masses (63 laparotomy, 11 thoracotomy, 12 both). Prognostic factors for relapse and survival were analysed with Kaplan-Meier curves and Cox regression analysis. Putative prognostic factors included age, the primary histology, prechemotherapy level of the tumour markers AFP and HCG, the extent of disease (lymph nodes, lung and hepatic metastases) before and after chemotherapy, the histology of the resected material and the completeness of the surgical procedure. Eleven patients relapsed during follow-up (median 47 months), accounting for a 5 year relapse free percentage of 87.4%. Adverse prognostic factors were (1) prechemotherapy level of HCG (> or = 10,000 IU l-1; (2) incomplete resection; and (3) the extent of disease, especially of lung metastases (prechemotherapy number < or = 3,4-19, > or = 20; or size after chemotherapy > 1 cm; or presence of any residual lung metastasis after chemotherapy without residual abdominal metastases). The histology found at resection was not associated with the risk of relapse, which might be explained by the effectiveness of postresection chemotherapy, which in the majority of these patients was a salvage regimen rather than two further cycles of the initial cytostatics. A good and a poor risk group were formed, based on HCG level and completeness of resection. The effect of salvage chemotherapy after resection of viable cancer cells needs further investigation.

MeSH Terms
Adult Antineoplastic Combined Chemotherapy Protocols/therapeutic use Dysgerminoma/drug therapy,mortality,surgery Follow-Up Studies Humans Male Multivariate Analysis Neoplasm Metastasis Neoplasm Staging Prognosis Retrospective Studies Survival Analysis Teratoma/drug therapy,mortality,pathology,surgery Testicular Neoplasms/drug therapy,mortality,pathology,surgery Time Factors
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Steyerberg E W
Department of Clinical Oncology, Urology and Thoracic Surgery, University Hospital Leiden, The Netherlands.
Keizer H J
Zwartendijk J
Van Rijk G L
Van Groeningen C J
Habbema J D
Stoter G
References (18)
18 references, click to expand
  1. Non-seminomatous germ cell testicular tumours: residual masses after chemotherapy.
    Br J Surg. 1985 Jan;72(1):19-22 PMID: 2578300
  2. Is postchemotherapy retroperitoneal surgery necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses?
    J Clin Oncol. 1992 Apr;10(4):569-73 PMID: 1312586
  3. Testicular cancer.
    Acta Oncol. 1988;27(4):439-53 PMID: 3060153
  4. Prognostic factors for relapse after complete response in patients with metastatic germ cell tumors.
    Cancer. 1989 Feb 1;63(3):440-5 PMID: 2912523
  5. The role of surgery in metastatic testicular germ cell tumours (GCT).
    Br J Cancer. 1989 Jun;59(6):837-9 PMID: 2544224
  6. Ten-year survival and late sequelae in testicular cancer patients treated with cisplatin, vinblastine, and bleomycin.
    J Clin Oncol. 1989 Aug;7(8):1099-104 PMID: 2474060
  7. Excision of residual masses after platinum based chemotherapy for non-seminomatous germ cell tumours.
    Eur J Cancer Clin Oncol. 1989 Dec;25(12):1689-94 PMID: 2561098
  8. The importance of prognostic factors in the individual treatment of patients with disseminated germ cell tumours.
    Br J Urol. 1990 Oct;66(4):425-9 PMID: 2224438
  9. Evaluation of survival data and two new rank order statistics arising in its consideration.
    Cancer Chemother Rep. 1966 Mar;50(3):163-70 PMID: 5910392
  10. Post-chemotherapy surgery in advanced non-seminomatous germ-cell testicular tumours: the significance of histology with particular reference to differentiated (mature) teratoma.
    Br J Cancer. 1984 Nov;50(5):601-9 PMID: 6093838
  11. The role of surgery in advanced testicular cancer.
    Cancer. 1984 Dec 1;54(11 Suppl):2716-21 PMID: 6388814
  12. Treatment of testicular cancer: a new and improved model.
    J Clin Oncol. 1990 Nov;8(11):1777-81 PMID: 1700077
  13. Prognostic factors in unselected patients with nonseminomatous metastatic testicular cancer: a multicenter experience.
    J Clin Oncol. 1991 May;9(5):818-26 PMID: 1707957
  14. Combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for metastatic testicular teratoma: long-term follow-up.
    Eur J Cancer. 1991;27(6):684-91 PMID: 1712606
  15. Long-term follow-up of non-seminomatous testicular cancer patients with mature teratoma or carcinoma at postchemotherapy surgery. EORTC Genitourinary Tract Cancer Cooperative Group (EORTC GU Group)
    Eur J Cancer. 1991;27(6):695-8 PMID: 1829907
  16. Assessment of risk in metastatic testis carcinoma: impact on treatment.
    Urol Int. 1991;46(3):298-303 PMID: 1656578
  17. The Second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors. Medical Research Council Testicular Tumour Working Party.
    J Clin Oncol. 1992 Jan;10(1):85-94 PMID: 1309383
  18. Correlation of computerized tomographic changes and histological findings in 80 patients having radical retroperitoneal lymph node dissection after chemotherapy for testis cancer.
    J Urol. 1987 Jun;137(6):1176-9 PMID: 3035236
Article Info
Journal
British journal of cancer
Abbr.
Br J Cancer
ISSN
0007-0920
Published
1993-07-00
Pages
195-200
Language
English
Region
England
NLM ID
0370635
PMCID
PMC1968324
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]